Member Info for chester18

I realise there are many blood tests and health checks prior to any patient being given our SCIB 1 injection. So considering how long it has been since the initial enrollment date was announced, should we be right to expect a 'first patient' RNS about now?

Chester.

I really enjoy this channel, all the science bits, the news on potential deals, the mystery's like when will the trial really start and some of the adlib comedy especially but the continual re-runs of Neighbours, East Enders and Coronation Street just dampen my enthusiasm.

So can we have more of the upto date forward looking stuff please.

Yours a disgruntled consumer....

Chester.

Your suggestion would mean that the Market Capitalisation would be around £400M which is probably way to high. Maybe after a successful phase 2b trial where due to orphan status the FDA gave the procedure full approval. Maybe then the price would be so high.
My presumption is that a very positive RNS will push the share price over £5.00. We will have to wait and see but I am confident it will be good news just how good is the question.

Chester.

It seems to me that the 12 month delay waiting for the TriGrid 2 had definitely slowed us down, But....
Lindy is always looking to improve the percentage of patients that will get the benifit.
So the SCIB 1 trial will be a success if the number of responders heads North of 50%.
In all medical breakthrough's there are always some unlucky patients left behind, what Scancell will aim to achieve is to find the keys to help all patients.
That's not a bad ideal is it.

There will always be competition but I hope the boot will be on the foot and Scancell will be the disruptive force upsetting big pharma's dominance.

Chester.

Cheers Tom

Very happy with that price , it could easily have gone the other way .

Chester.

Having asked for some sage advice from this board on Sunday I've watched the share price bounce around all week and finally decided to invest in another 273700 odd shares. Trying to catch the very bottom of the current prices could mean missing on any decent rise so I've taken the plunge. Thank you to those that responded to my questions.

Onwards and upwards, as the saying goes.

Chester.

Just catching up with the days trades. Those large, late trades are not just pocket change so has the fact that Scancell will be presenting six 'bang on point' posters at very prestigious event, got someone very excited.
Those kinds of transactions usually happen on positive news so they are by there isolation and size very interesting.

Saying that I wish I had a spare £36k to increase my SCLP holding.

Chester.

Looks like some form of transfer.
The 11.00am 202k trade countered by the late trade of 202k. If the time stamps are factually correct one was a buy and the other a sell. Seems plausible to me that it is a transfer of sorts.

Chester.

Your welcome but the thanks goes to Chelsea7 on the SCLP board who mentioned it yesterday.

When posting, copy your text prior to hitting the post button.
If it just disappears just paste the text and re-post straight away.

I've just done that and it seems to work consistently ..

Chester.

Hi BTB,

I had downloaded the Newcrest presentation but not watch the actual presentation. It does make it more real actually heading the CEO talk in those terms about the GGP discovery at Hav.

Thank you to all those who have responded so far. I'll make my investment decision on Monday morning. Hopefully it's not already up by 20% at the open...

Chester.

Hi Bewarethebrokers

Yes I've watched all the Proactive Investers interviews and GH always gives a cool and level-headed interview. But I surpose that's why I'm asking my question. If I've absorbed all of the positive vibe coming out of Newcrest, GGP and the wider media and I can't see any 'problem', then why are so many selling into every rise?
I want to invest but I am also concerned I don't know all of the practical reasons this particular JV could end in tears. I don't expect that to happen so asking for some Sage advice.

Chester

I've read every post on this board for the last 3-4 weeks and the information from contributers is on the whole extremely informative and accurate.
In general most of the posts are very positive with a few just showing that they are fed up because they've not already doubled their investment.
So I ask a simple question to the more experienced posters,
What could make the current situation unravel?

I've thought it through and with all the activity on the ground and the CEO of Newcrest being so blatantly positive I've already convinced myself that investing more into GGP is a 'no brainer'.
So before I take the plunge are their any wise old sages out there that can see any pot holes or any negatives.

Chester.

Morning Bewise,

I'm interested in your thoughts regarding the European Conference on the 29th Sept.
VRP state in the RNS that they will be presenting based on the Ensifentrine data released in March and August of this year.
I'm intrigued to know if you think they may have some upto date data they will share at this Conference.
They must have a good reason to be presenting and justifying the cost.

I still have my 5k of shares and will continue to hold as I still believe that in the future Ensifentrine will prove to be of great benefit to people suffering from COPD.

Chester.

I watched the You Tube extract that you put up and I agree it was very unprofessional to say if CTX didn't work they would just throw it away. I can only suggest that those ill chosen words were due solely to nerves at the beginning of his presentation.
However, later in the Q&A he talked about the RP results and stated very clearly that if the improvement seen in the first 3 patients started to decline they would inform the market as it was it would be of major importance to the stockholder to be informed.
We have heard nothing and they have taken on new staff whose only job is to deal with the positive outcome of a Successful Trial.
So I do feel we are only waiting for a very good RNS on RP.

Chester

Seeingtom thank you,

The actual business by which I mean the medical products that the TRX group produce are a real step into the future for the repair or replacement of human biological parts. Sports injury, Dental repair, Heart Valve replacement, Bone repair etc etc......
Those medical advances will only increase in popularity over time so would anticipate that TRX shares would be in greater and greater demand, but at the moment they are held in check.
My main question :
Right now in 2019 is the business only worth £39M Market Cap?
TRX has cash in the bank for approx six months plus all the assets of Cellright and a growing order book. Add to that a growing turnover of approx £13M in 2019 and budgeted to grow to £18M in 2020.

I think there are three distinct brakes acting on the share price, Woodford, Brexit and being on the AIM market.
Two of which the company just can't control.

If the management continue to keep there focus to grow the business this could become a very important and valuable company.

Chester.

Hi Crumbs

I had shares in Oxfordbiomedica when they needed funds to build their manufacturing plant. Rather that dilute the shareholders Vulpes brokered a financial loan package to see them to their first big deal.
Martin Diggle alluded to that in his response on Thursday..
I actually wouldn't mind further shares being issued if it meant we brought on board another investor like Vulpes.
It's a bit like Dragon's Den where you benifit far more from their experience and industry / financial contacts.
To me the tide has turned for Scancell in a massive way.
All we need is that precious positive data.... That's all... Lol

Chester.

Thank you 2cvguy and Miavoce its so useful to actually hear what and how things were presented at the AGM.

I listened to the recording whilst following the presentation notes put up by Innan.
I know we all thought by September 2019 Scancell would be flying but taking into consideration the pioneering nature of the science it is definitely going to be worth all the wait because the science is getting stronger, more robust and is now so much more 'on the money'... in my humble opinion..

The magnitude of possibilities are compelling.

For those who are still a little negative I do think that having Patience is a problem if you had already banked on this paying off your mortgage or if you've over invested your capital at 20p a share and you could really do with having some of it back now rather that in two years but you have an investment in a company right on the cutting edge of Cancer Immuno Therapy.

So excited for our journey over the next 12 - 18 months, by then one, two or three data reports could be in...

Obviously a proud member of team positive ...

Chester.

Is there not one other investor in TRX that can be bothered to add a comment.
This still a solid company even though circumstances have dragged down the price or is this the correct level at this time ???

Chester.

If you are John Chiplin it would seem this board has been pumped for info, so any success is down to us and I think in that case we all deserve some free shares.... Lol....